Glenn L. Cooper MD

This profile gathers the share dealings of Glenn L. Cooper MD across 3 companies, led by Repligen Corp, Indevus Pharmaceuticals Inc and Fortress Biotech, Inc. In total, 27 filings cover trades dated from 9 January 2006 to 23 May 2019.

Market trades split into 7 purchases (€166k) and 4 sales (€599k). The net balance comes to €433k on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 12 share grants and 2 option exercises. So far in 2019, the count stands at no purchases and 4 sales.

Half of the purchases are above €17k and half below. After 5 purchases with a full 90-day history, the hit rate stands at 80% and the median 90-day move at +2.1%. This is a record of the past, not a forecast.

On 19 June 2019 came the latest disclosure, an option exercise for €107k in Repligen Corp. The clock since the last published purchase (3 December 2012) now reads 5,089 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.